Spots Global Cancer Trial Database for A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants
Official Title: A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants
Study ID: NCT04487405
Conditions
Interventions
Study Description
Brief Summary: The objective of this project is to validate the sensitivity, specificity, positive predictive value and negative predictive values of the AMRA blood test for assessing risk of cancer in women at high risk for ovarian cancer, due to the presence of a symptomatic adnexal mass.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Women's Health Arizona, Chandler, Arizona, United States
Altus Research, Lake Worth, Florida, United States
MidTown OBGYN, Columbus, Georgia, United States
Premier OBGYN of Minnesota, Eden Prairie, Minnesota, United States
Square Care Health, New Hyde Park, New York, United States
Northwell Health, New Hyde Park, New York, United States
Seven Hills Clinical Research Group, Cincinnati, Ohio, United States
May Grant OB/GYN, Lancaster, Pennsylvania, United States
Hill Country OBGYN Associates, Austin, Texas, United States
Contact Details
Name: Todd Pappas, PhD
Affiliation: Aspira Women's Health
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
